Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2009
Linac-based isocentric electron-photon treatment of radically operated breast carcinoma with enhanced dose uniformity in the field gap areaMikko Tenhunen, Heidi Nyman, Satu Strengell, et al.
Duodecim; Laaketieteellinen Aikakauskirja|April 4, 2009
[Is lymphoma curable with antibody therapy?]Sirpa Leppä, Heidi Nyman, Marja-Liisa Karjalainen-Lindsberg
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 2, 2010
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patientsSari Riihijärvi, Satu Koivula, Heidi Nyman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 19, 2009
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOPHeidi Nyman, Mats Jerkeman, Marja-Liisa Karjalainen-Lindsberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisoneMinna Taskinen, Marja-Liisa Karjalainen-Lindsberg, Heidi Nyman, et al.
Acta Oncologica (Stockholm, Sweden)|December 14, 2011
Submandibular gland-sparing intensity modulated radiotherapy in the treatment of head and neck cancer: sites of locoregional relapse and survivalJuhani Collan, Mika Kapanen, Antti Mäkitie, et al.
European Journal of Haematology|January 15, 2009
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomasHeidi Nyman, Mats Jerkeman, Marja-Liisa Karjalainen-Lindsberg, et al.
Leukemia & Lymphoma|July 3, 2010
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapyKarin Rydström, Johan Linderoth, Heidi Nyman, et al.
Blood|February 15, 2007
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapyHeidi Nyman, Magdalena Adde, Marja-Liisa Karjalainen-Lindsberg, et al.
British Journal of Haematology|August 24, 2006
Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOPAntti Harjunpää, Minna Taskinen, Matti Nykter, et al.
Pageof 1